Literature DB >> 12918131

Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.

Fariborz Mansour-Ghanaei1, Najaf Dehbashi, Kamyar Yazdanparast, Afshin Shafaghi.   

Abstract

AIM: To compare the efficacy of antibiotics therapy alone with antibiotics and saccharomyces boulardii in treatment of acute amebiasis.
METHODS: In a double blind, random clinical trial on patients with acute intestinal amoebiasis, 57 adult patients with acute amoebiasis, diagnosed with clinical manifestations (acute mucous bloody diarrhea) and amebic trophozoites engulfing RBCs found in stool were enrolled in the study. Regimen 1 included metronidazole (750 mg Tid) and iodoquinol (630 mg Tid) for 10 days. Regimen 2 contained capsules of lyophilized saccharomyces boulardii (250 mg Tid) orally in addition to regimen 1. Patients were re-examined at two and four weeks after the treatment, and stool examination was performed at the end of week 4. Student's t-test, chi(2) and McNemar's tests were used for statistical analysis.
RESULTS: Three patients refused to participate. The other 54 patients were randomized to receive either regimen 1 or regimen 2 (Groups 1 and 2 respectively, each with 27 patients). The two groups were similar regarding their age, sex and clinical manifestations. In Group 1, diarrhea lasted 48.0+/-18.5 hours and in Group 2, 12.0+/-3.7 hours (P<0.0001). In Group 1, the durations of fever and abdominal pain were 24.0+/-8.8 and 24.0+/-7.3 hours and in Group 2 they were 12.0+/-5.3 and 12.0+/-3.2 hours, respectively (P<0.001). Duration of headache was similar in both groups. At week 4, amebic cysts were detected in 5 cases (18.5 %) of Group 1 but in none of the Group 2 (P<0.02).
CONCLUSION: Adding saccharomyces boulardii to antibiotics in the treatment of acute amebiasis seems to decrease the duration of clinical symptoms and cyst passage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918131      PMCID: PMC4611554          DOI: 10.3748/wjg.v9.i8.1832

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Probiotics and infectious diarrhea.

Authors:  J Saavedra
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum.

Authors:  I Castagliuolo; J T LaMont; S T Nikulasson; C Pothoulakis
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

4.  Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926).

Authors:  J Müller; N Remus; K H Harms
Journal:  Mycoses       Date:  1995 Mar-Apr       Impact factor: 4.377

5.  [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study].

Authors:  H Kollaritsch; H Holst; P Grobara; G Wiedermann
Journal:  Fortschr Med       Date:  1993-03-30

6.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

7.  Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum.

Authors:  C Pothoulakis; C P Kelly; M A Joshi; N Gao; C J O'Keane; I Castagliuolo; J T Lamont
Journal:  Gastroenterology       Date:  1993-04       Impact factor: 22.682

8.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.

Authors:  K Plein; J Hotz
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

9.  Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines.

Authors:  J P Buts; N De Keyser; L De Raedemaeker
Journal:  Pediatr Res       Date:  1994-10       Impact factor: 3.756

10.  Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.

Authors:  C M Surawicz; G W Elmer; P Speelman; L V McFarland; J Chinn; G van Belle
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

View more
  19 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection.

Authors:  Ener Cagri Dinleyici; Makbule Eren; Nihal Dogan; Serap Reyhanioglu; Zeynel Abidin Yargic; Yvan Vandenplas
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

Review 3.  Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.

Authors:  Jean-Paul Buts
Journal:  Dig Dis Sci       Date:  2008-06-05       Impact factor: 3.199

4.  Probiotics to prevent the need for, and augment the use of, antibiotics.

Authors:  Gregor Reid
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

5.  The Potential of Lactobacillus casei and Entercoccus faecium Combination as a Preventive Probiotic Against Entamoeba.

Authors:  Nitya Sarjapuram; Niharika Mekala; Meetali Singh; Utpal Tatu
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

6.  Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.

Authors:  Grettel García-Collinot; Eduardo Osiris Madrigal-Santillán; Michel A Martínez-Bencomo; Rosa A Carranza-Muleiro; Luis J Jara; Olga Vera-Lastra; Daniel H Montes-Cortes; Gabriela Medina; María Pilar Cruz-Domínguez
Journal:  Dig Dis Sci       Date:  2019-09-23       Impact factor: 3.199

Review 7.  Probiotics in infectious diarrhoea in children: are they indicated?

Authors:  Y Vandenplas; S Salvatore; M Vieira; M Viera; T Devreker; B Hauser
Journal:  Eur J Pediatr       Date:  2007-07-05       Impact factor: 3.183

8.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

Review 9.  Probiotics in the management of Giardia duodenalis: an update on potential mechanisms and outcomes.

Authors:  Nasrin Dashti; Mitra Zarebavani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-07-29       Impact factor: 3.000

10.  Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Authors:  Rima Hatoum; Steve Labrie; Ismail Fliss
Journal:  Front Microbiol       Date:  2012-12-19       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.